Sfoglia per RIVISTA
FUTURE ONCOLOGY (LONDON, ENGLAND)
Collezione AOU Novara

  

Items : 3

Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. in Future oncology (London, England) / Future Oncol. 2022 Sep;18(27):2987-2997. doi: 10.2217/fon-2022-0484. Epub 2022 Aug 11.

2022
AOU Novara

Harrison CN; Gupta VK; Gerds AT; Rampal R; Verstovsek S; Talpaz M; Kiladjian JJ; Mesa R; Kuykendall AT; Vannucchi AM; Palandri F; Grosicki S; Devos T; Jourdan E; Wondergem MJ; Al-Ali HK; Buxhofer-Ausch V; Alvarez-Larrán A; Patriarca A; Kremyanskaya M; Mead AJ; Akhani S; Sheikine Y; Colak G; Mascarenhas J;

Combi-TED: a new trial testing Tedopi(®) with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line. in Future oncology (London, England) / Future Oncol. 2022 Dec;18(40):4457-4464. doi: 10.2217/fon-2022-0913. Epub 2023 Mar 22.

2022
AOU Novara

Landi L; Delmonte A; Bonetti A; Pasello G; Metro G; Mazzoni F; Borra G; Giannarelli D; Andrikou K; Mangiola D; Gori S; D'Andrea MR; Minuti G; Resuli B; Laudisi A; Vidiri A; Conti L; Cappuzzo F;

FISH in triple-negative breast cancer: a possible strategy for the future? in Future oncology (London, England) / Future Oncol. 2015;11(7):1023-6. doi: 10.2217/fon.15.25.

2015
AOU Novara

Rigon E; Saggia C; Rossi V; Genestroni S; Gaudino E; Campisi P; Veggiani C; Boldorini RL; Alabiso O;